Active Antitumor Immunity Elicited by Vaccine Based on Recombinant Form of Epidermal Growth Factor Receptor
Authors:
- Bing HuBHBing Hu
- Yuquan WeiYWYuquan Wei
- Ling TianLTLing Tian
- Xia ZhaoXZXia Zhao
- You LuYLYou Lu
- Yang WuYWYang Wu
- Bing YaoBYBing Yao
- Jiyan LiuJLJiyan Liu
- Ting NiuTNTing Niu
- Yanjun WenYWYanjun Wen
- Qiuming HeQHQiuming He
- Jingmei SuJSJingmei Su
- 1 May 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 28 (3) , 236-244
Abstract
Active immunotherapy targeting epidermal growth factor receptor (EGFR) should be another attractive approach to the treatment of EGFR-positive tumors. To test this concept, the authors evaluated the potential immune responses and antitumor activities elicited by dendritic cells pulsed with recombinant ectodomain of mouse EGFR (DC-edMER). Spleen cells isolated from DC-edMER-vaccinated mice showed a high quantity of EGFR-specific antibody-producing cells. EGFR-reactive antibody in sera isolated from vaccinated mice was identified and shown to be effective against tumors in vitro and in vivo by adoptive transfer. DC-edMER vaccine also elicited cytotoxic T-lymphocyte responses that could mediate antitumor effects in vitro and adoptive transfer in vivo. In addition, EGFR-specific cytokines responses were elicited by DC-edMER vaccine. Immunization with DC-edMER resulted in tumor regression and prolonged survival in mice challenged with Lewis lung carcinomas and mammary cancer models. Depletion of CD4+ T lymphocytes could completely abrogate the antitumor activity and EGFR-specific antibody responses, whereas the depletion of CD8+ T lymphocytes showed partial abrogation of the antitumor activity but antibody was still detected. Furthermore, tumor-induced angiogenesis was suppressed in DC-edMER-vaccinated mice or mice treated with antibody adoptive transfer. Taken together, these findings suggest the antitumor immunity could be induced by DC-edMER, which may involve both humoral and cellular immunity, and may provide insight into the treatment of EGFR-positive tumors through the induction of active immunity against EGFR.Keywords
This publication has 44 references indexed in Scilit:
- Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigenOncogene, 2001
- Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cellsOncogene, 1997
- The Th1/Th2 paradigmImmunology Today, 1997
- Control of EGF Receptor Signaling by Clathrin-Mediated EndocytosisScience, 1996
- The expanding universe of T-cell subsets: Th1, Th2 and moreImmunology Today, 1996
- RECEPTORS FOR EPIDERMAL GROWTH FACTOR AND OTHER POLYPEPTIDE MITOGENSAnnual Review of Biochemistry, 1987
- Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequencesNature, 1984
- The erbB gene of avian erythroblastosis virus is a member of the src gene familyCell, 1983
- Asymptotically Efficient Rank Invariant Test ProceduresJournal of the Royal Statistical Society. Series A (General), 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958